INTRA-CELLULAR THERAPIES INC COM 주식 (NASDAQ: ITCI)

에 대한 최신 뉴스 INTRA-CELLULAR THERAPIES INC COM (NASDAQ:ITCI) 주식

INTRA-CELLULAR THERAPIES INC

Intra-Cellular Therapies

Johnson.Johnson&Johnson

Technicals

Trading Ideas

ITCI

존슨앤드존슨(NYSE:JNJ)의 주가는 수요일 1% 이상 상승 마감했다. 어제, 주가는 7.5% 이상 하락했다. 분석가들은 이 회사가 인트라셀룰러 테라피스(NASDAQ:ITCI)를 인수하기로 한 발표가 수익을 희석시킬 것이라고 언급한 것이 하락의 원인이라고 설명한다.

오늘의 주식: 존슨앤드존슨 주가가 반등할까? 지지선에 부딪힌 매도세는 끝났을지도

MicroStrategy. Photo by JOCA_PH on Shutterstock

Equities

Large Cap

News

Movers

BLDR

CVNA

HEES

HOOD

MSTR

SOFI

XPEV

1월 13일부터 1월 17일까지 지난주 최고의 성과를 낸 대형주 11종목은 다음과 같다. 여러분의 포트폴리오에도 포함되어 있는지 확인해 보자.  마이크로스트레티지, 소파이 테크놀로지스, 카바나, 인트라 셀룰라, 로빈후드, 베이진, JD닷컴, 빌더스 퍼스트소스, 심보틱, 샤오펑, 유나이티드 렌탈스

마이크로스트레티지, 소파이 테크놀로지스, 카바나 등 지난주 급등한 대형주 (1월 13일~17일)

Delta Airlines

CTTAF

FTAI

NVDA

RPRX

SNAP

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 월그린스 부츠 얼라이언스(NASDAQ:WBA)의 주가가 회사가 예상보다 나은 1분기 재무결과를 발표한 후 27.97% 상승했다.

월그린스, 마이크론 및 델타 항공은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (1월 6일-10일)

INTRA-CELLULAR THERAPIES INC COM

Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $126.67, along with a high estimate of $132.00 and a low estimate of $100.00. This current average has increased by 7.65% from the previous average price target of $117.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631256_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Intra-Cellular Therapies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$132.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$132.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Intra-Cellular Therapies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>Unveiling the Story Behind Intra-Cellular Therapies</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Intra-Cellular Therapies: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Intra-Cellular Therapies's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 51.49%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -8.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intra-Cellular Therapies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.47%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews

Shares of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are trading higher on Wednesday. <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44594161/johnson-johnson-stock-is-tumbling-tuesday-what-going-on">Yesterday, they were down more than 7.5%</a>.  Analysts attribute the move lower to the company's announcement that its pending acquisition of Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) will dilute its earnings.
But the sell-off may have ended, and there is a good chance Johnson &amp; Johnson rallies. This is why our team of trading experts has made it our Stock of the Day.
You can see on the chart below that the selloff ended when the shares reached the $153 level. This wasn't a coincidence. This price level was resistance in November. Price levels that had been resistance converting into support is a frequent occurrence in the financial markets.
It is due to investor and trader psychology.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1024x529.png" alt="" class="wp-image-853722" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4.png 1615w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44609851/from-seashells-to-satoshi-why-cryptocurrency-is-the-next-natural-evolution-of-money">From Seashells To Satoshi: Why Cryptocurrency Is The Next Natural Evolution Of Money</a>
Some people who sold Johnson &amp; Johnson around $153.00 thought they made a good decision to sell when the price trended lower after. But when the resistance was broken in February, many of these unhappy sellers second-guessed themselves.
Some believed their decision to sell was a mistake and vowed to return their shares. But they would only do so if they could eventually get them at the same price they were sold for.
As a result, when the shares fell to around $153 yesterday, these formerly happy sellers entered the market as buyers. There were so many of them that it put a floor beneath the price. It created support at the same price that had been resistance.
Johnson &amp; Johnson may reverse and move higher.
Some of the buyers who formed this support may become concerned that they will be outbid. They may think there are others who would be willing to pay higher prices than they will, and they know that these are the sellers who will go to them.
Because of this, they increase their bid prices to get ahead of other buyers. Other concerned buyers could see this, and raise their bid prices to get ahead of others as well.
This dynamic could result in a bidding war that forces Johnson &amp; Johnson into an uptrend.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44607188/arthur-hayes-predicts-bitcoin-to-hit-250000-by-end-of-year">Arthur Hayes Predicts Bitcoin To Hit $250,000 By End Of Year</a></li>
</ul>
Image: Shutterstock

Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended

Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Neutral and maintains $132 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Neutral on Intra-Cellular Therapies, Maintains $132 Price Target

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for major <a target="_blank" href="https://www.benzinga.com/news/large-cap" rel="noreferrer noopener">depressive disorder (aMDD)</a>.
The move follows insufficient efficacy in the target patient population. The data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified.
The company <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-ventura-program" rel="noreferrer noopener">will</a> explore future development opportunities for aticaprant. Full analyses from the VENTURA development program are underway and will be shared at a future medical meeting.
In January, &nbsp;Neumora Therapeutics, Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) released data from the Phase 3 KOASTAL-1 Study of navacaprant for <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42763345/neumora-therapeutics-depression-drug-fails-in-first-of-three-pivotal-phase-3-trials" rel="noreferrer noopener">major depressive disorder</a>.
The study did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale.
Navacaprant, like aticaprant, is a kappa opioid receptor antagonist. Johnson &amp; Johnson says it continues to build on its leadership in Neuroscience.
In January, the healthcare giant agreed to acquire&nbsp;Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) for $132.00 per share in cash for a total equity value of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" rel="noreferrer noopener">approximately $14.6 billion</a>.
Johnson &amp; Johnson&#8217;s other depression drug Spravato (esketamine), in January, received FDA approval as the only monotherapy for adults living with major depressive disorder who have had an inadequate response to at least <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43105398/fda-approves-johnson-johnsons-treatment-as-first-monotherapy-for-treatment-resistant-depression" rel="noreferrer noopener">two oral antidepressants</a>.
In 2024, Spravato generated global sales of <a target="_blank" href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue" rel="noreferrer noopener">around $1.01 billion</a>. In May 2024, Johnson &amp; Johnson&nbsp;topline results from Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39069469/johnson-johnsons-drug-seltorexant-aces-late-stage-depression-trial" rel="noreferrer noopener">with insomnia symptoms</a>.
The study achieved all primary and secondary endpoints, with seltorexant demonstrating both a statistically significant and clinically meaningful improvement in depressive symptoms and improved sleep disturbance outcomes in patients who had a prior inadequate response to SSRI/SNRI antidepressants alone.
Price Action: JNJ stock is down 0.20% at $165.50 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" target="_blank" rel="noreferrer noopener">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

General

NMRA

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Mizuho cut Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) price target from $140 to $132. Mizuho analyst Graig Suvannavejh downgraded the stock from Outperform to Neutral. Intra-Cellular Therapies shares closed at $128.60 on Friday. <a href="https://www.benzinga.com/quote/ITCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from $33 to $26. Goldman Sachs analyst Leah Jordan downgraded the stock from Buy to Neutral. Conagra shares closed at $25.79 on Friday. <a href="https://www.benzinga.com/quote/CAG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) price target from $13 to $10. B of A Securities analyst John Murphy downgraded the stock from Neutral to Underperform. Rivian Automotive, shares closed at $12.97 on Friday. <a href="https://www.benzinga.com/quote/RIVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut the price target for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from $101 to $85. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Block shares closed at $68.35 on Friday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup slashed the price target for NICE Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) from $279 to $228. Citigroup analyst Tyler Radke maintained a Buy rating. NICE shares closed at $155.39 on Friday. See how other <a href="https://www.benzinga.com/quote/NICE/analyst-ratings">analysts view this stock</a>.</li>
<li>RBC Capital cut Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) price target from $50 to $43. RBC Capital analyst Steven Shemesh maintained a Sector Perform rating. Wayfair shares settled at $41.83 on Friday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital slashed Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) price target from $117 to $110. Loop Capital analyst Jeffrey Stevenson maintained a Hold rating. Louisiana-Pacific shares closed at $98.71 on Friday. <a href="https://www.benzinga.com/quote/LPX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Scotiabank raised Nutrien Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) price target from $60 to $62. Scotiabank analyst Ben Isaacson maintained a Sector Outperform rating. Nutrien shares closed at $52.59 on Friday.  <a href="https://www.benzinga.com/quote/ntr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies raised the price target for NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from $75 to $115. Jefferies analyst Randal Konik upgraded the stock from Hold to Buy. Nike shares settled at $76.50 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel boosted Floor &amp; Decor Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) price target from $100 to $110. Stifel analyst W. Andrew Carter upgraded the stock from Hold to Buy. Floor &amp; Decor shares closed at $94.27 on Friday. <a href="https://www.benzinga.com/quote/fnd/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43909524/top-3-tech-stocks-that-may-crash-in-q1">Top 3 Tech Stocks That May Crash In Q1</a></li>
</ul>

Markets

NICE

RIVN

Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo analyst Derek Archila downgraded the rating for Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Overweight to Equal-Weight and maintained the price target of $36. Exelixis shares closed at $36.85 on Friday. <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst John Murphy downgraded Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Neutral to Underperform and lowered the price target from $13 to $10. Rivian Automotive shares closed at $12.97 on Friday. <a href="https://www.benzinga.com/quote/RIVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Leah Jordan downgraded Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from Buy to Neutral and lowered the price target from $33 to $26. Conagra Brands shares closed at $25.79 on Friday. <a href="https://www.benzinga.com/quote/CAG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Stephen Grambling downgraded Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) from Overweight to Equal-Weight and lowered the price target from $82 to $81. Boyd Gaming shares closed at $76.86 on Friday. <a href="https://www.benzinga.com/quote/BYD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Graig Suvannavejh downgraded the rating for Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Outperform to Neutral and slashed the price target from $140 to $132. Intra-Cellular Therapies shares closed at $128.60 on Friday. <a href="https://www.benzinga.com/quote/ITCI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CAG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="515" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132029/image-195-1024x515.png" alt="" class="wp-image-796086" style="width:573px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132029/image-195-1024x515.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132029/image-195-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132029/image-195-768x386.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24132029/image-195.png 1148w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43909524/top-3-tech-stocks-that-may-crash-in-q1">Top 3 Tech Stocks That May Crash In Q1</a></li>
</ul>

Downgrades

EXEL

This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Mizuho analyst Graig Suvannavejh downgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Outperform to Neutral and lowers the price target from $140 to $132.

Mizuho Downgrades Intra-Cellular Therapies to Neutral, Lowers Price Target to $132

In the last three months, 4 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $124.0, a high estimate of $132.00, and a low estimate of $100.00. This current average has increased by 14.29% from the previous average price target of $108.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175266_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Intra-Cellular Therapies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$132.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$132.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Intra-Cellular Therapies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>Get to Know Intra-Cellular Therapies Better</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Understanding the Numbers: Intra-Cellular Therapies's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of 39.23% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -15.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.3%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.99%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Intra-Cellular Therapies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Hold to Hold.

Needham Reiterates Hold on Intra-Cellular Therapiesto Hold

Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 44.83 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $199.22 million which beat the analyst consensus estimate of $193.40 million by 3.01 percent. This is a 50.81 percent increase over sales of $132.10 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Intra-Cellular Therapies Q4 EPS $(0.16) Misses $(0.11) Estimate, Sales $199.22M Beat $193.40M Estimate

On Tuesday, Axsome Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)&nbsp;reported fourth-quarter 2024 revenues of $118.77 million, up from $71.53 million a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $117.64 million.</a>
Auvelity (oral antidepressant) net product sales for the quarter were $92.6 million, up 89% year over year. Approximately 158,000 prescriptions were written for Auvelity in the fourth quarter of 2024, representing an increase of 87% and 10% compared to the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43776882/axsome-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-busin" rel="noreferrer noopener">third quarter of 2024</a>.
Sunosi (sleep disorder) net product revenues were $26.2 million, up 16%. Approximately 49,000 prescriptions were written for Sunosi, representing an increase of 16% year-over-year and 4% sequentially.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As &#8216;Top Pick For 2025&#8217;</a>
The company reported a net loss of $1.54 per share compared to $2.08 per share a year ago, missing the consensus of $(1.03).
Anticipated Milestones
<ul>
<li>The company expects to submit a new drug application for AXS-14 for fibromyalgia in the first half of 2025, a delay <a href="https://www.benzinga.com/pressreleases/24/11/g41896353/axsome-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update" target="_blank" rel="noreferrer noopener">from November 2024</a>.</li>
<li>Axsome anticipates new drug application submission for AXS-05 for Alzheimer&#8217;s disease agitation and AXS-12 for narcolepsy in the second half of 2025.</li>
<li>The company expects clinical data from a Phase 3 EMERGE trial of AXS-07 in migraine in 1Q 2025.</li>
<li>Data from Phase 3 FOCUS trial of solriamfetol in ADHD in adults and Phase 3 PARADIGM trial in major depressive disorder in Q1 2025.</li>
<li>The company anticipates data from the Phase 3 ENGAGE trial of solriamfetol in binge eating disorder and the Phase 3 SUSTAIN trial in shift work disorder in 2026.</li>
<li>A pivotal Phase 2/3 trial of AXS-05 in smoking cessation is expected to be initiated in 2025.</li>
</ul>
In January, the FDA approved Axsome Therapeutics&#8217; Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43351848/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-acute-tre" rel="noreferrer noopener">without aura in adults</a>.
The company expects SYMBRAVO to be commercially available in the U.S. in approximately four months.
William Blair sees Axsome&#8217;s AXS-05 as a unique drug with strong safety advantages. Analyst Myles Minter is optimistic about its approval chances, citing positive results from the ADVANCE-1, ACCORD-1, and ACCORD-2 trials and its breakthrough therapy designation.
With peak sales expected to surpass $1 billion for Alzheimer &#8216;s-related agitation, William Blair considers this expansion a major growth driver for Axsome. The firm also notes potential M&amp;A interest, especially given Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" rel="noreferrer noopener">pending $14.6 billion</a> acquisition of Intra-Cellular Therapies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>).
Price Action:&nbsp;AXSM shares are down 3% at $127.22&nbsp;on the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43776626/totalenergies-powers-up-with-air-liquide-in-a-628-million-hydrogen-breakthrough" target="_blank" rel="noreferrer noopener">TotalEnergies Powers Up With Air Liquide For Hydrogen Breakthrough</a></li>
</ul>

AXSM

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst

Canaccord Genuity analyst Sumant Kulkarni downgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Buy to Hold and raises the price target from $119 to $132.

Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold, Raises Price Target to $132

In the preceding three months, 6 analysts have released ratings for Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $108.83, a high estimate of $132.00, and a low estimate of $89.00. Observing a 9.56% increase, the current average has risen from the previous average price target of $99.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1737579616_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Intra-Cellular Therapies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$132.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Intra-Cellular Therapies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Intra-Cellular Therapies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>About Intra-Cellular Therapies</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Key Indicators: Intra-Cellular Therapies's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Intra-Cellular Therapies displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 39.23%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -15.03%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Intra-Cellular Therapies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.3%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.99%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Intra-Cellular Therapies's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RBC Capital analyst Brian Abrahams downgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Outperform to Sector Perform and raises the price target from $108 to $132.

RBC Capital Downgrades Intra-Cellular Therapies to Sector Perform, Raises Price Target to $132

On Wednesday,&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.01</a>.
The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43122545/johnson-johnson-reports-q4-and-full-year-2024-results" rel="noreferrer noopener">of $22.44 billion</a>.
Operational growth was 6.7%, and adjusted&nbsp;operational growth was 5.7%.
Innovative Medicine sales increased to $14.33 billion, up 4.4% (+6.1% adjusted operational).
Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine), driven by continued strong share gains and market growth. Overall cancer sales increased to $5.49 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43105398/fda-approves-johnson-johnsons-treatment-as-first-monotherapy-for-treatment-resistant-depression" rel="noreferrer noopener">FDA Approves Johnson &amp; Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression</a>
Growth was partially offset by Stelara (ustekinumab). Stelara sales&nbsp;<a target="_blank" href="http://Johnson &amp; Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments." rel="noreferrer noopener">fell</a> 14.7% to $2.35 billion. Darzalex sales rose 20.9% to $3.08 billion. The company's cancer cell therapy, Carvykti, generated sales of $334 million.
MedTech sales increased 6.7% to 8.19 billion, <a target="_blank" href="https://s203.q4cdn.com/636242992/files/doc_financials/2024/q4/Final-JNJ-Earnings-Presentation-4Q2024-Webcast.pdf" rel="noreferrer noopener">driven</a> by global procedure growth, new product performance, and the Shockwave deal. Growth was partially offset by endocutter products in Advanced Surgery.
Guidance:&nbsp;Johnson &amp; Johnson expects 2025 sales of $90.9 billion—$91.7 billion, compared to the consensus of $90.99 billion. The Medtech giant expects 2025 adjusted EPS of $10.75–$10.95 versus a consensus of $10.59.
The company expects to accelerate the launch of newly launched products in the MedTech segment, with the full benefit of the Shockwave acquisition through May. JNJ sees normalized procedure volume and seasonality.
Earlier this month, Johnson &amp; Johnson&nbsp;agreed to acquire&nbsp;Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) for $132.00 per share in cash for a total equity value of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" rel="noreferrer noopener">approximately $14.6 billion</a>.
Intra-Cellular Therapies is a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders.
Price Action: At last check on Wednesday, JNJ stock was down 1.69% to $145.65 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43124298/aptiv-unplugs-eds-spin-off-aims-to-supercharge-electrification-automation-and-ai" target="_blank" rel="noreferrer noopener">Aptiv Unplugs EDS: Spin-Off Aims To Supercharge Electrification, Automation And AI</a></li>
</ul>
Image By Sundry Photography Via Shutterstock

Guidance

Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook

As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">BridgeBio Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>)</h3>
<ul>
<li>On Nov. 22, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.. The company's stock surged around 28% over the past month and has a <a href="https://www.benzinga.com/quote/BBIO">52-week high of $41.04</a>.</li>
<li>RSI Value: 71.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>BBIO Price Action: Shares of BridgeBio Pharma fell 0.9% to close at $33.79 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>)</h3>
<ul>
<li>On Jan. 15, Intuitive Surgical reported strong preliminary fourth-quarter results. "We are pleased with customer adoption of da Vinci 5, Ion, and SP during the quarter and full year. We remain focused on delivering the goals we share with our customers, centered on improving patient outcomes," said Gary Guthart, CEO of Intuitive Surgical. The company's stock gained around 9% over the past five days and <a href="https://www.benzinga.com/quote/ISRG">has a 52-week high</a> of $597.68.</li>
<li>RSI Value: 72.6</li>
<li>ISRG Price Action: Shares of Intuitive Surgical gained 1.5% to close at $592.64 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Boston Scientific Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</h3>
<ul>
<li>On Jan. 8, Boston Scientific agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and peripheral artery disease. The company's stock gained around 11% over the past month and has a <a href="https://www.benzinga.com/quote/BSX">52-week high</a> of $99.14.</li>
<li>RSI Value: 75.3</li>
<li>BSX Price Action: Shares of Boston Scientific gained 0.5% to close at $98.66 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Intra-Cellular Therapies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)</h3>
<ul>
<li>On Jan. 13, Johnson &amp; Johnson entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies for $132 per share in cash in a deal that values the company at approximately $14.6 billion. The company's stock jumped around 51% over the past month and has a 52-week high is $128.00.</li>
<li>RSI Value: 85.6</li>
<li>ITCI Price Action: Shares of Intra-Cellular Therapies fell 0.05% to close at $126.20 on Friday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43054647/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Short Ideas

Pre-Market Outlook

BBIO

ISRG

Top 4 Health Care Stocks You May Want To Dump In Q1

These eleven large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock surged 33.02% after Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) entered into a definitive agreement to acquire the company for $132 per share in cash, valuing <a href="https://www.benzinga.com//node/42959061" target="_blank" rel="noreferrer noopener">it at approximately $14.6 billion</a>. A couple of analysts <a href="https://www.benzinga.com/quote/itci/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded the stock</a>.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock grew 20.92% on <a href="https://www.benzinga.com//node/43062726" target="_blank" rel="noreferrer noopener">Bitcoin's continued upward momentum</a>.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) stock upped 20.13% after announcing a $45 million <a href="https://www.benzinga.com//node/42971991" target="_blank" rel="noreferrer noopener">settlement with the SEC</a>.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) stock rose 19.39% after Hindenburg Research, which previously issued a short report on the stock, <a href="https://www.benzinga.com//node/43034961" target="_blank" rel="noreferrer noopener">announced it would close down</a>.</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) shares gained 18.88% last week.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) shares were up 17.82% on the acceleration of China's economic activity, beating expectations for the last quarter of 2024 <a href="https://www.benzinga.com//node/43062957" target="_blank" rel="noreferrer noopener">as stimulus measures kicked in</a>.</li>
<li>Builders FirstSource, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) stock upped 17.26%.</li>
<li>SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) shares escalated 16.61%. The company disclosed a personal loan securitization agreement <a href="https://www.benzinga.com//node/43037459" target="_blank" rel="noreferrer noopener">with a global fixed-income manager on Thursday</a>.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares increased 16.30% after the company announced an agreement to acquire Walmart Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) <a href="https://www.benzinga.com//node/43026684" target="_blank" rel="noreferrer noopener">Advanced Systems and Robotics business</a>. Northland Capital Markets maintained an Outperform rating while raising the price <a href="https://www.benzinga.com/quote/sym/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast to $41 from $35</a>.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) stock gained 15.63% last week after China's central bank <a href="https://www.benzinga.com//node/42974632" target="_blank" rel="noreferrer noopener">reportedly indicated</a> it would take measures to support economic growth. China's GDP growth data also <a href="https://www.benzinga.com//node/43062957" target="_blank" rel="noreferrer noopener">fueled optimism</a>.</li>
<li>United Rentals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) stock upped 14.91% after announcing <a href="https://www.benzinga.com//node/42974291" target="_blank" rel="noreferrer noopener">it would acquire</a> H&amp;E Equipment Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEES#NASDAQ">HEES</a>) for $4.8 billion. Additionally, Baird upgraded the stock <a href="https://www.benzinga.com/quote/uri/analyst-ratings" target="_blank" rel="noreferrer noopener">from Underperform to Neutral</a>.</li>
</ol>
Photo by JOCA_PH on Shutterstock

MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

Piper Sandler analyst David Amsellem downgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Overweight to Neutral and raises the price target from $107 to $132.

Piper Sandler Downgrades Intra-Cellular Therapies to Neutral, Raises Price Target to $132

<h3>Gainers</h3>
<ul>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock increased by 185.6% to $4.47 during Monday's pre-market session. The market value of their outstanding shares is at $6.4 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock moved upwards by 141.42% to $4.08. The market value of their outstanding shares is at $7.0 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock moved upwards by 69.84% to $2.14. The company's market cap stands at $8.5 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) stock increased by 38.01% to $7.66. The company's market cap stands at $468.5 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock moved upwards by 34.76% to $127.85. The market value of their outstanding shares is at $13.5 billion. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares rose 34.02% to $1.3. The market value of their outstanding shares is at $16.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock fell 31.4% to $4.1 during Monday's pre-market session. The company's market cap stands at $237.3 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares fell 27.47% to $0.59. The company's market cap stands at $2.9 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares decreased by 21.51% to $2.08. The market value of their outstanding shares is at $4.6 million. </li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares decreased by 21.02% to $33.37. The market value of their outstanding shares is at $12.8 billion. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock fell 19.4% to $1.33. The market value of their outstanding shares is at $39.3 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 19.19% to $0.15. The market value of their outstanding shares is at $11.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

AIRS

ATPC

DYAI

GTBP

KAPA

MRNA

NAYA

PHIO

SAGE

SLRX

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of Intra-Cellular Therapies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) are trading higher Monday after Johnson &amp; Johnson agreed to <a href="https://www.benzinga.com/pressreleases/25/01/g42940221/johnson-johnson-strengthens-neuroscience-leadership-with-acquisition-of-intra-cellular-therapies-i">acquire the company</a>.
What To Know: Johnson &amp; Johnson on Monday entered into a definitive agreement to acquire all outstanding shares of Intra-Cellular Therapies for $132 per share in cash in a deal that values the company at approximately $14.6 billion. 
The acquisition is expected to strengthen Johnson &amp; Johnson&#8217;s presence in neuroscience, and includes Intra-Cellular Therapies&#8217; CAPLYTA (lumateperone), a once-daily oral treatment approved by the FDA for schizophrenia and depressive episodes linked to bipolar I and II disorder.
Johnson &amp; Johnson also gains a pipeline, including ITI-1284, which is being tested for generalized anxiety disorder and Alzheimer's-related psychosis and agitation.
In December 2024, Intra-Cellular Therapies submitted a supplemental new drug application for CAPLYTA as an adjunctive treatment for major depressive disorder. If approved, the drug could become a key player in treating common depressive disorders, potentially generating over $5 billion in annual sales.
The transaction is expected to close later this year, pending regulatory and shareholder approvals. Once completed, Intra-Cellular Therapies&#8217; stock will be delisted from the Nasdaq. Johnson &amp; Johnson plans to fund the acquisition with cash on hand and debt. Johnson &amp; Johnson is also expected to provide commentary on any potential impact to adjusted earnings when it reports financial results on Jan. 22. 
ITCI Price Action: Intro-Cellular shares were up 34.2% at $127.27 at the time of writing Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="523" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-1024x523.png" alt="" class="wp-image-731191" style="width:493px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-1024x523.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-768x392.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08-1536x784.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13142141/Screenshot-2025-01-13-at-14.15.08.png 1546w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42958251/on-semi-sees-utilization-cuts-as-ev-demand-softens-analyst-warns">ON Semi Sees Utilization Cuts As EV Demand Softens, Analyst Warns</a></li>
</ul>
Photo by solarseven on Shutterstock.

Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?

Legal

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders

Small Cap

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, HEES, SSTK on Behalf of Shareholders

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK and ITCI on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITCI, PWOD, EBTC on Behalf of Shareholders

CCNE

EBTC

EDBL

ENFN

LGTY

LTRPA

LTRPB

OMIC

PWOD

SSTK

Cantor Fitzgerald

Mizuho

Canaccord Genuity

RBC Capital

Piper Sandler

존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)의 주가는 수요일 1% 이상 상승 마감했다. <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44594161/johnson-johnson-stock-is-tumbling-tuesday-what-going-on">어제, 주가는 7.5% 이상 하락했다</a>. 분석가들은 이 회사가 인트라셀룰러 테라피스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)를 인수하기로 한 발표가 수익을 희석시킬 것이라고 언급한 것이 하락의 원인이라고 설명한다.
하지만 매도세는 끝났을 수도 있으며, 존슨앤드존슨이 랠리를 보일 가능성이 크다. 그래서 우리의 거래 전문가 팀은 이를 &#8216;<a href="https://kr.benzinga.com/?s=%EC%98%A4%EB%8A%98%EC%9D%98+%EC%A3%BC%EC%8B%9D" target="_blank" rel="noopener">오늘의 주식</a>&#8216;으로 선정했다.
아래 차트에서 볼 수 있듯이, 매도세는 주가가 $153 수준에 도달했을 때 끝났다. 이는 우연이 아니었다. 이 가격 수준은 11월에 저항선이었다. 저항선이 지지선으로 전환되는 현상은 금융 시장에서 자주 발생한다.
이는 투자자와 거래자의 심리에 기인한다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-853722" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1024x529.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02122026/one4.png 1615w" alt="" width="1024" height="529" /></figure>
또한 읽어보세요: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44609851/from-seashells-to-satoshi-why-cryptocurrency-is-the-next-natural-evolution-of-money">조개껍데기에서 사토시까지: 암호화폐가 화폐의 다음 자연스러운 진화인 이유</a>
주가가 약 $153.00에서 매도한 일부 사람들은 이후 가격이 하락하자 매도 결정을 잘 내렸다고 생각했다. 그러나 2월에 저항선이 뚫리면서, 이들 중 많은 불행한 판매자들은 자신의 결정을 의심하게 되었다.
일부는 매도 결정이 실수라고 생각하고 자신들의 주식을 되찾겠다고 다짐했다. 하지만 그들은 판매했던 가격에 맞춰서만 되돌려 받을 수 있을 것이라고 생각했다.
결과적으로, 어제 주가가 약 $153로 떨어졌을 때, 이들 이전에 행복했던 판매자들이 구매자로 시장에 들어왔다. 그들의 수가 너무 많아 가격에 하한선을 형성했다. 이는 저항선이었던 가격에서 지지선이 형성되었다.
존슨앤드존슨은 반전하여 상승할 수 있다.
이 지지를 형성한 일부 구매자들은 자신들이 입찰에서 밀릴까 걱정할 수 있다. 그들은 자신보다 더 높은 가격을 지불할 의향이 있는 사람들이 있다는 것을 알고 있으며, 이들은 자신들에게 판매할 판매자들이다.
이 때문에 그들은 다른 구매자들보다 앞서기 위해 입찰 가격을 높인다. 다른 걱정하는 구매자들도 이를 보고 다른 사람들보다 앞서기 위해 입찰 가격을 올릴 수 있다.
이 역동성은 존슨앤드존슨이 상승세로 나아가도록 강요하는 입찰 전쟁을 초래할 수 있다.
주가 움직임: 존슨앤드존슨의 주식은 수요일 1.38% 상승한 $155.36에 마감되었다.

다음 읽어볼 내용:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44607188/arthur-hayes-predicts-bitcoin-to-hit-250000-by-end-of-year">아서 헤이즈, 비트코인 연말까지 $250,000 도달 예측</a></li>
</ul>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

1월 13일부터 1월 17일까지 지난주 최고의 성과를 낸 대형주 11종목은 다음과 같다. 여러분의 포트폴리오에도 포함되어 있는지 확인해 보자.
<ol>
<li>인트라 셀룰라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>): 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)이 주당 132달러 현금으로 인트라 셀룰라를 인수하기로 최종 합의하면서 주가는 지난주 33.02% 급등했다. 해당 인수 거래 거래는 <a href="https://www.benzinga.com//node/42959061" target="_blank" rel="noreferrer noopener">약 146억 달러</a>로 평가되며, 일부 애널리스트들이 <a href="https://www.benzinga.com/quote/itci/analyst-ratings" target="_blank" rel="noreferrer noopener">인트라 셀룰라 투자의견을 하향 조정</a>했다.</li>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>): <a href="https://www.benzinga.com//node/43062726" target="_blank" rel="noreferrer noopener">비트코인의 지속적인 상승 모멘텀</a>으로 20.92% 상승했다.</li>
<li>로빈후드 마켓츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 미 증권거래위원회(SEC)와 <a href="https://www.benzinga.com//node/42971991" target="_blank" rel="noreferrer noopener">4,500만 달러 합의</a> 발표 후 20.13% 상승했다.</li>
<li>카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>): 힌덴버그 리서치가 카바나 주식에 대한 공매도 보고서를 발표한 이후 <a href="https://www.benzinga.com//node/43034961" target="_blank" rel="noreferrer noopener">폐업을 발표</a>하면서 19.39% 상승했다.</li>
<li>베이진(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>): 지난주에 18.88% 상승했다.</li>
<li>JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>): 중국 경제 활동의 가속화로 주가는 17.82% 상승했다. 이는 2024년 4분기 기대치를 초과하는 <a href="https://www.benzinga.com//node/43062957" target="_blank" rel="noreferrer noopener">경기 부양 조치가 시행됨</a>에 따른 것이었다.</li>
<li>빌더스 퍼스트소스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>):지난주에 17.26% 상승했다.</li>
<li>소파이 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>): 회사가 <a href="https://www.benzinga.com//node/43037459" target="_blank" rel="noreferrer noopener">글로벌 채권 투자 관리자와의 개인 대출 유동화 계약을 발표</a>한 후 16.61% 상승했다.</li>
<li>심보틱(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>): 월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)의 <a href="https://www.benzinga.com//node/43026684" target="_blank" rel="noreferrer noopener">고급 시스템 및 로봇 사업부 인수 계약</a>을 발표한 이후 주가는 16.30% 상승했다. 노스랜드 캐피털 마켓츠(Northland Capital Markets)는 심보틱에 대한 시장수익률 상회 의견을 유지하고 목표주가는 <a href="https://www.benzinga.com/quote/sym/analyst-ratings" target="_blank" rel="noreferrer noopener">35달러에서 41달러로 상향 조정했다.</a></li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>): 중국 인민은행이 <a href="https://www.benzinga.com//node/42974632" target="_blank" rel="noreferrer noopener">경제성장 지원 조치를 취할 것이라고 보도</a>한 후 15.63% 상승했다. 중국의 GDP 데이터도 <a href="https://www.benzinga.com//node/43062957" target="_blank" rel="noreferrer noopener">낙관론을 부추겼다.</a></li>
<li>유나이티드 렌탈스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>): H&amp;E 이큅먼트 서비시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEES#NASDAQ">HEES</a>)를 <a href="https://www.benzinga.com//node/42974291" target="_blank" rel="noreferrer noopener">48억 달러에 인수하기로 발표한 후 14.91% 상승했다.</a> 또한, 베어드는 유나이티드 렌탈스에 대한 투자의견을 시장수익률 하회에서 중립으로 상향 조정했다.</li>
</ol>
사진 출처: Shutterstock의 JOCA_PH
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)의 주가가 회사가 <a href="https://www.benzinga.com//node/42912519" target="_blank" rel="noreferrer noopener">예상보다 나은</a> 1분기 재무결과를 발표한 후 27.97% 상승했다.
2. 콘스텔레이션 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)의 주가가 회사가 전력 생산 회사인 칼파인(Calpine Corp.)을 현금 및 주식 <a href="https://www.benzinga.com//node/42916941" target="_blank" rel="noreferrer noopener">164억 달러로 평가된 인수 계약</a>을 발표한 후 25.80% 급등했다.
3. FTAI 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>)의 주가가 20.48% 상승했다.
4. TD 시넥스 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>)의 주가가 회사가 <a href="https://www.benzinga.com//node/42915528" target="_blank" rel="noreferrer noopener">예상보다 나은 4분기 재무결과</a>를 발표한 후 15.05% 상승했다.
5. 오로라 이노베이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>)의 주가가 회사가 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 및 콘티넨탈 AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CTTAF#OTC">CTTAF</a>)와의 파트너십을 발표한 후 14.59% 상승했다. 이 파트너십은 엔비디아의 <a href="https://www.benzinga.com//node/42841305" target="_blank" rel="noreferrer noopener">차세대 DRIVE Thor SoC</a>를 사용하여 무인 트럭을 확장하는 것이다.
6. 로열티 파마(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)의 주가가 회사가 <a href="https://www.benzinga.com//node/42902266" target="_blank" rel="noreferrer noopener">분기 배당금을 인상했다고 발표</a>한 후 14.35% 상승했다.
7. 마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)의 주가가 13.75% 상승했다. 회사는 퓨어 스토리지(Pure Storage)와의 협력을 확장하여 고용량, 에너지 효율적인 <a href="https://www.benzinga.com//node/42853369" target="_blank" rel="noreferrer noopener">마이크론 G9 QLC NAND를 사용한 솔루션</a>을 개발한다고 발표했다.
8. 델타항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>)의 주가가 회사가 <a href="https://www.benzinga.com//node/42912208" target="_blank" rel="noreferrer noopener">예상보다 나은 실적을 발표하고 2025년 가이던스를 발표</a>한 후 13.34% 상승했다.
9. 인트라셀룰라 테라피(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)의 주가가 12.62% 상승했다. 회사는 산도즈(Sandoz)와 화해 계약을 체결하고 CAPLYTA Patent와 관련된 특허 소송을 해결했다.
10 유나이티드 에어라인 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) 주가가 델타 항공와 동반 상승하여 12.24% 급등했다. 델타 항공는 <a href="https://www.benzinga.com//node/42919651" target="_blank" rel="noreferrer noopener">4분기 재무결과가 좋다고 발표</a>한 후 상승했다.
사진 출처: VanderWolf via Shutterstock


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>빌리빌리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>)의 주가는 지난주 &#8216;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#8217; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 <a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">21</a>달러 가격 목표를 발표했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주가는 안크티바(ANKTIVA)가 여러 주에 걸쳐 <a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">첫 번째 상용 투여량</a>을 투여한 보험 적용 범위를 발표한 이후 지속적인 강세로 22.36% 상승했다.</li>
<li>사솔(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>)은 회사가 법원에서 회사와 토탈에너지스 SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) 마켓팅에 유리한 판결을 내렸다고 발표한 후 주가는 20.89% 상승했다. 또한 손해배상금으로 38.9억 랜드, <a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이자로 약 2,300만 랜드</a>를 받았다.</li>
<li>지난주 올리즈 바겐 아울렛 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>)의 주식은 JP모건이 중립에서 <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">비중확대</a>로 평가를 올린 이후 15.25% 상승했다.</li>
<li>인트라-셀룰러 테라피스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 회사가 루마테페론을 주요 우울 장애 환자를 위한 보조 요법으로 평가하고 <a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">1차 및 주요 2차 평가변수를 충족</a>시키는 두 번째 3상 시험의 톱라인 결과를 발표한 후 주가는 13.18% 상승했다.      shares advanced 12.06% on overall strength in chip stocks. Also, B. Riley Securities analyst <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">raised the price forecast</a> on the stock from $45 to $50.</li>
<li>앰코 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>)는 전반적인 칩주 강세로 주가는 12.06% 상승했다. 또한 B. 라일리 증권(B. Riley Securities)의 분석가는 주식 가격 <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">예측</a>을 45달러에서 50달러로 높였다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)는 회사가 이전에 공개한 <a href="https://www.benzinga.com//node/39411935" target="_blank" rel="noreferrer noopener">제조 자동화 계획</a>의 초기 단계를 시작한 후 기업의 이정표에 도달했다고 발표한 후 주가는 11.53% 증가했다.</li>
<li>로켓 랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)는 주가는 <a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">일본 기업 신스펙티브(Synspective)</a>와 도쿄에서 10개 제품 출시 계약을 체결한 후 11.32% 상승했다.</li>
<li>브레드 파이낸셜 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>)는 에버코어 ISI 그룹(Evercore ISI Group)이 이 주식을 언더퍼폼(Underperform)에서 인-라인(In-Line)으로 평가를 올리고 목표 주가를 42달러에서 45달러로 <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한 </a>이후 10.81% 상승했다. 또한 또한 RBC 캐피털은 해당 주식에 대해 섹터 퍼폼(Sector Perform) 등급을 유지하고 목표 주가를 38달러에서 45달러로 높였다.</li>
<li>BRF S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>)의 주식은 10.69% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

AMKR

BILI

BRFS

IBRX

IRTC

OLLI

RKLB

TALO

빌리빌리와 올리즈 바겐은 지난주 최대 성과를 보인 10개 중형주 중 일부 (6월 16일-6월 22일)

수요일 오전 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 월스트리트는 애벗 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)가 개장 전에 98억 8천만 달러의 매출과 주당 95센트의 분기 수익을 보고할 것으로 예상하고 있다. 애벗 주식은 시간 외 거래에서 1% 상승한 110.30달러를 기록했다.
인트라-셀룰러 테라피즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 5억 달러 규모의 보통주 공모 제안을 공개했다. 인트라-셀룰러 테라피즈의 주가는 시간외 거래에서 1.3% 하락한 78.80달러를 기록했다.
분석가들은 U.S. 뱅코프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>)의 67억 2천만 달러의 매출과 주당 88센트의 분기 이익을 기록할 것으로 예상하고 있다. 회사는 시장 개장 전에 수익을 발표할 예정이다. U.S. 뱅코프의 주가는 시간외 거래에서 0.6% 하락한 40.75달러를 기록했다.
여기에서 <a href="https://www.benzinga.com/premarket" target="_blank" rel="noopener">개장 전 시황</a>을 확인하세요. 
<div class="sc-bdZQJD kfHPIH all-devices">
<div class="ad-container">
<div class="sc-iLWhZk iosiT">
<div class="adunitContainer"></div>
</div>
</div>
</div>
온트랙(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>)은 예상보다 저조한 4분기 재무 결과를 보고했다. 회사는 주당 21센트의 손실에 대한 시장 기대와 비교하여 주당 27센트의 조정 손실을 기록했습니다. 회사의 분기별 매출은 353만 9천 달러로 추정치인 403만 7천 달러를 놓쳤다. 온트랙 주가는 시간외 거래에서 14.2% 하락한 0.3949달러를 기록했다.
분석가들은 트래블러스 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>)가 개장 전에 105억 1천만 달러의 분기 매출과 주당 4.90달러 이익을 기록할 것으로 예상했다. 트래블러스의 주식은 시간외 거래에서 0.8% 상승한 224.98달러를 기록했다.
확인해 보세요: <a href="https://www.benzinga.com/news/24/04/38268727/top-4-tech-stocks-you-may-want-to-dump-in-april" target="_blank" rel="noopener">4월에 투매하고 싶은 상위 4개 기술주</a>

Penny Stocks

OTRK

애벗 래버러토리스, U.S. 뱅코프 및 수요일에 주목해야 할 3가지 주식

Comments

INTRA-CELLULAR THERAPIES INC COM

뉴스

에 대한 최신 뉴스 INTRA-CELLULAR THERAPIES INC COM (NASDAQ:ITCI) 주식

목요일, 4월 03, 2025

일요일, 1월 19, 2025

일요일, 1월 12, 2025

월요일, 6월 24, 2024

수요일, 4월 17, 2024

뉴스

파트너 / 기고자

벤징가 글로벌